<DOC>
	<DOCNO>NCT01703221</DOCNO>
	<brief_summary>The purpose study assess efficacy omarigliptin 25 mg weekly ( monotherapy ) compare sitagliptin 50 mg daily placebo , long term safety ( 52 week ) omarigliptin 25 mg weekly . The primary hypothesis 24 week : 1 ) Omarigliptin 25 mg weekly provide great reduction baseline glycosylated hemoglobin ( HbA1c ) compare placebo , 2 ) The mean change baseline HbA1c participant treat omarigliptin 25 mg weekly non-inferior compare participant treat sitagliptin 50 mg daily .</brief_summary>
	<brief_title>Omarigliptin ( MK-3102 ) Clinical Trial - Placebo- Sitagliptin-Controlled Monotherapy Study Japanese Patients With Type 2 Diabetes Mellitus ( MK-3102-020 )</brief_title>
	<detailed_description>The treatment period compose 24-week double-blind period ( Phase A ) 28-week open-label period ( Phase B ) . Participants receive Phase A : omarigliptin 25 mg weekly , sitagliptin 50 mg daily placebo Phase B : omarigliptin 25 mg weekly .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Has type 2 diabetes mellitus History type 1 diabetes mellitus history ketoacidosis History follow medication : thiazolidinediones and/or insulin within 12 week prior study participation , omarigliptin and/or sitagliptin anytime</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>